Showing 5791-5800 of 5956 results for "".
- Oculus Announces Release of Smartfield Smart Compact Perimeterhttps://modernod.com/news/oculus-announces-release-of-smartfield-smart-compact-perimeter/2479897/Oculus has announced the release of its Smartfield perimeter, expanding its portfolio of compact visual field testing devices. The new Smartfield has been optimized specifically for examinations for functional impairment of the central visual field, but is also suited for peripheral measurements.
- Apellis Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophyhttps://modernod.com/news/apellis-announces-first-patient-dosed-in-its-phase-3-clinical-program-for-apl-2-in-patients-with-geographic-atrophy/2479898/Apellis Pharmaceuticals announced that it has commenced its phase 3 clinical program for APL-2 in patients with geographic atrophy (GA), consisting of two phase 3 trials (DERBY & OAKS.) The first patient has been dosed in the OAKS trial and the first patient has been enrolled in the
- New Joystick for the Keratograph 5M With Release Functionhttps://modernod.com/news/new-joystick-for-the-keratograph-5m-with-release-function/2479900/The Oculus Keratograph 5M now comes equipped with a new joystick, which includes a release function. The new feature enables the user to capture images and video sequences with the push of a button on the device. No need any more to switch to the mouse – the user’s hand stays resting on the new
- Adolescents With Strabismus More Likely to Have Psychological Problemshttps://modernod.com/news/adolescents-with-strabismus-more-likely-to-have-psychological-problems/2479912/Adolescents with visible eye deviation due to strabismus may be prone to psychological problems, researchers in Turkey report. “The visible eye deviation caused by strabismus was a strong indicator of psychological distress in
- Dompé Receives FDA Approval of Oxervate, the First Drug for Neurotrophic Keratitishttps://modernod.com/news/dompe-receives-fda-approval-of-oxervate-a-first-in-class-treatment-of-neurotrophic-keratitis/2479916/The FDA has approved the first drug to treat neurotrophic keratitis, a rare and progressive eye disease that can lead to corneal scarring and vision loss. Oxervate (cenegermin-bkbj ophthalmic solution), which is manufactured by Italian pharmaceutical company Dompé, is based on cenegermin-b
- FDA Approves First Drug for Neurotrophic Keratitishttps://modernod.com/news/fda-approves-first-drug-for-neurotrophic-keratitis/2479917/The FDA approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea. “While the prevalence of neurotrophic keratitis is low, the impact of this serious condition on an individual patient can be devastating,” Wiley Chamber
- Staying Fit Might Cut Glaucoma Riskhttps://modernod.com/news/staying-fit-might-cut-glaucoma-risk/2479921/Meeting physical activity guidelines and being physically fit may reduce the risk of developing glaucoma by 40 percent to 50 percent, recent research suggests, according to a Reuters
- CDC Launches the Nation’s First Vision and Eye Health Surveillance Systemhttps://modernod.com/news/cdc-launches-the-nations-first-vision-and-eye-health-surveillance-system/2479924/The Centers for Disease Control and Prevention (CDC) has developed the nation’s first Vision and Eye Health Surveillance System (VEHSS). Launched in collaboration with the National Opinion Research Center (NORC), the VEHSS is designed to help health care professionals, researchers, policymakers,
- Penn’s Experimental Gene Therapy Saves Night Vision in Dogs, Paving the Way for Human Testshttps://modernod.com/news/penns-experimental-gene-therapy-saves-night-vision-in-dogs-paving-the-way-for-human-tests/2479925/In 1990, scientists discovered a genetic mutation that turns an important light-sensing protein in the retina into a toxin that steadily destroys the ability to see in low light. <
- EyeGate Announces Enrollment of First Patient in PRK Pilot Studyhttps://modernod.com/news/eyegate-announces-enrollment-of-first-patient-in-prk-pilot-study/2479928/EyeGate Pharmaceuticals announced that the first patient has been enrolled in its pilot study evaluating the ability of EyeGate’s Ocular Bandage Gel (OBG) to accelerate re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK) surgery.